Last edition
News about "Emily Ruiz"
US FDA Approves Label Update for Sun Pharma's UNLOXCYT
Sun Pharma has received US FDA approval for a label update to UNLOXCYT, the first and only PD-L1 inhibitor for advanced Cutaneous Squamous Cell Carcinoma (aCSCC), further supporting its clinical value with durable responses and a favourable safety profile for patients with multiple comorbidities.
Emily Ruiz | 27/11/2025 | By Dineshwori | 175
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members